The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students

Influenza Clinical Trial

Official title:

The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine Administrated Alone and Concomitantly With a Quadrivalent Inactivated Influenza Vaccine in Junior High School Students

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06208683
• Other study ID #: PRO-MUM-MA4001-SN
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: November 4, 2023
• Est. completion date: December 1, 2024

Study information

• Verified date: November 2023
• Source: Sinovac Biotech Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a randomized, controlled, open-label phase Ⅳ clinical trial of a live attenuated mumps vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. The purpose of this study is to evaluate the immunogenicity and safety of the booster doses of a mumps vaccine administrated alone and concomitantly with a quadrivalent inactivated influenza vaccine in healthy junior high school students. And the cross-neutralization of mumps vaccine immune serum and mumps virus strains

Description:

This study is an open-lable, randomised, controlled phase Ⅳ clinical trial in healthy junior high school students to the immunogenicity and safety of the booster doses of a mumps vaccine (MV) administrated alone and concomitantly with a quadrivalent influenza vaccine (QIV) in healthy junior high school students. The experimental vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd. A total of 400 healthy students will be enrolled, including 300 students who have received one dose of mumps-containing vaccine (MCV) before vaccination, and 100 students who have received two doses of mumps-containing vaccine before vaccination. 300 students with a history of 1 dose of MCV will be randomly divided into 3 groups in a ratio of 1:1:1, and will receive 1 dose of MV alone, 1 dose of QIV alone, or 1 dose of MV and 1 dose of QIV simultaneously. Students with a history of 2 doses of MCV received 1 dose of MV alone. Blood samples were collected before and 30 days after vaccination. Pre-vaccination blood samples were used to detect antibody levels of measles, mumps, influenza and varicella, and post-vaccination blood samples were used to detect mumps antibodies and/or influenza antibodies corresponding to the vaccination.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 400
• Est. completion date: December 1, 2024
• Est. primary completion date: February 2, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Healthy junior high school students;

• subjects and/or guardians who can understand and voluntarily sign the informed consent form (For subjects aged 8-17 years, both subjects and guardians need to sign the informed consent form)

• Provision of valid identification.;

• History of 1 or 2 doses of mumps-containing vaccine;

Exclusion Criteria:

• History of mumps or have completed 3 doses of mumps-containing vaccine;

• Receipt of the current seasonal influenza vaccine (except subjects in Arm 4)

• History of asthma or allergy to the vaccine or vaccine components, or serious adverse reactions to the vaccine, such as urticaria, dyspnea,and angioedema;

• Congenital malformations or developmental disorders, genetic defects, severe malnutrition;

• Autoimmune disease (such as systemic lupus erythematosus) or a state of immunodeficiency / immunosuppression (such as AIDS, after organ transplantation);

• Severe chronic diseases, severe cardiovascular diseases, hypertension and diabetes that cannot be controlled by drugs, liver or kidney diseases, malignant tumors, etc.;

• Severe neurological disease (epilepsy, convulsions or convulsions) or mental illness;

• Thyroid disease or history of thyroidectomy, asplenia, functional asplenia, any condition resulting in asplenia or splenectomy;

• Abnormal coagulation function diagnosed by a doctor (such as coagulation factor deficiency, coagulation disease, platelet abnormality) or obvious bruising or coagulation disorder;

• Immunosuppressive therapy, cytotoxic therapy, inhaled corticosteroids (excluding corticosteroid spray therapy for allergic rhinitis, topical corticosteroid therapy for acute uncomplicated dermatitis) within the past 6 months;

• Receipt of blood products in the past 3 months;

• Receipt of other investigational drugs in the past 30 days;

• Receipt of attenuated live vaccines in the past 28 days;

• Receipt of inactivated or subunit vaccines in the past 7 days;

• Onset of various acute or chronic diseases within 7 days prior to the study;

• Axillary temperature >37.0°C;

• Participation in other clinical trials before enrollment and during the follow-up period, or a plan to participate in other clinical trials within 3 months.

• Any other factors that are unsuitable for participating in this clinical trial according to the investigator's judgment

Related Conditions & MeSH terms

• Influenza
• Influenza, Human
• Mumps

Intervention

Biological:
• Mumps vaccine, Live (MV)
0.5mL per dose,containing =3.7 lg CCID50 live mumps virus
• Influenza Vaccine, inactivated, quadrivlent(QIV)
0.5mL per dose, containing 4 strains of influenza virus recommended by the WHO, 15ug of each strain.

Locations

Country	Name	City	State
China	Qindu Distric Center for Disease Prevention and Control	Xianyang	Shaanxi
China	Xingping Center for Disease Prevention and Control	Xianyang	Shaanxi
China	Yuyang Distict Center for Disease Prevention and Control	Yulin	Shaanxi

Sponsors (1)

Lead Sponsor	Collaborator
Sinovac Biotech Co., Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric mean concentrations (GMCs) of mumps antibody	GMC s of mumps antibody 30 days after the vaccination of MV	30 days after the vaccination of MV
Secondary	Geometric mean increases (GMIs) of mumps antibody	Geometric mean increases (GMIs) of mumps antibody 30 days after the vaccination of MV	30 days after the vaccination of MV
Secondary	Seroconversion rate of mumps antibody	Seroconversion rate of mumps antibody 30 days after the vaccination of MV	30 days after the vaccination of MV
Secondary	Seropositivity rate of mumps antibody	Seropositivity rate of mumps antibody 30 days after the vaccination of MV	30 days after the vaccination of MV
Secondary	Geometric mean titers (GMTs) of influenza antibody	Geometric mean titers (GMTs) of influenza antibody 30 days after the vaccination of QIV	30 days after the vaccination of QIV
Secondary	Geometric mean increases (GMIs) of influenza antibody	Geometric mean increases (GMIs) of influenza antibody 30 days after the vaccination of QIV	30 days after the vaccination of QIV
Secondary	Seroconversion rate of influenza antibody	Seroconversion rate of influenza antibody 30 days after the vaccination of QIV	30 days after the vaccination of QIV
Secondary	Seropositivity rate of influenza antibody	Seropositivity rate of influenza antibody 30 days after the vaccination of QIV	30 days after the vaccination of QIV
Secondary	Geometric mean concentrations (GMCs) of mumps antibody 30 days after the simultaneous vaccination of MV and QIV	Geometric mean concentrations (GMCs) of mumps antibody	30 days after the simultaneous vaccination of MV and QIV
Secondary	Geometric mean titers (GMTs) of influenza antibody 30 days after the simultaneous vaccination of MV and QIV	Geometric mean titers (GMTs) of influenza antibody	30 days after the simultaneous vaccination of MV and QIV
Secondary	Geometric mean increases (GMIs) of mumps antibody and influenza antibody	Geometric mean increases (GMIs) of mumps antibody and influenza antibody 30 days after the simultaneous vaccination of MV and QIV	30 days after the simultaneous vaccination of MV and QIV
Secondary	Seroconversion rate of mumps antibody and influenza antibody	Seroconversion rate of mumps antibody and influenza antibody 30 days after the simultaneous vaccination of MV and QIV	30 days after the simultaneous vaccination of MV and QIV
Secondary	Seropositivity rate of mumps antibody and influenza antibody	Seropositivity rate of mumps antibody and influenza antibody 30 days after the simultaneous vaccination of MV and QIV	30 days after the simultaneous vaccination of MV and QIV
Secondary	The incidence of adverse reactions 0-7 days after vaccination	The incidence of adverse reactions 0-7 days after vaccination	0-7 days after vaccination
Secondary	The incidence of adverse reactions 0-14 days after vaccination	The incidence of adverse reactions 0-14 days after vaccination	0-14 days after vaccination
Secondary	The incidence of adverse reactions 0-30 days after vaccination	The incidence of adverse reactions 0-30 days after vaccination	0-30 days after vaccination
Secondary	Geometric mean concentrations (GMCs) of measles antibody before vaccination	Geometric mean concentrations (GMCs) of measles antibody before vaccination	before vaccination
Secondary	Geometric mean concentrations (GMCs) of rubella antibody before vaccination	Geometric mean concentrations (GMCs) of rubella antibody before vaccination	before vaccination
Secondary	Geometric mean titers (GMTs) of varicella-zostor antibody before vaccination	Geometric mean titers (GMTs) of varicella-zostor antibody before vaccination	before vaccination
Secondary	Geometric mean concentrations (GMCs) of mumps antibody before vaccination	Geometric mean concentrations (GMCs) of mumps antibody before vaccination	before vaccination
Secondary	Geometric mean titers (GMTs) of influenza antibody before vaccination	Geometric mean titers (GMTs) of influenza antibody before vaccination	before vaccination
Secondary	Seropositivity rate of measles antibody before vaccination	Seropositivity rate of measles antibody before vaccination	before vaccination
Secondary	Seropositivity rate of rubella antibody before vaccination	Seropositivity rate of rubella antibody before vaccination	before vaccination
Secondary	Seropositivity rate of varicella-zostor antibody before vaccination	Seropositivity rate of varicella-zostor antibody before vaccination	before vaccination
Secondary	Seropositivity rate of mumps antibody before vaccination	Seropositivity rate of mumps antibody before vaccination	before vaccination
Secondary	Seropositivity rate of influenza antibody before vaccination	Seropositivity rate of influenza antibody before vaccination	before vaccination
Secondary	Cross-neutralizing antibody titer of mumps vaccine	Cross-neutralizing antibody titer of mumps vaccine against different genotypes of mumps virus	30 days after the vaccination of MV alone or simultaneously with QIV